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Global view of the RAF-MeK-
eRK module and its immediate 
downstream effectors
Cristina C. santini 1,9, James Longden2, Erwin M. Schoof1, Craig D. simpson  2, 
Grace R. Jeschke  3, Pau Creixell4, Jinho Kim  5, Xuewei Wu6, Benjamin E. Turk3, 
Neal Rosen7, Poulikos I. Poulikakos6 & Rune Linding1,2,8
Small molecule inhibitors of BRAF and MEK have proven effective at inhibiting tumor growth in 
melanoma patients, however this efficacy is limited due to the almost universal development of 
drug resistance. To provide advanced insight into the signaling responses that occur following kinase 
inhibition we have performed quantitative (phospho)-proteomics of human melanoma cells treated 
with either dabrafenib, a BRAF inhibitor; trametinib, a MEK inhibitor or SCH772984, an ERK inhibitor. 
Over nine experiments we identified 7827 class I phosphorylation sites on 4960 proteins. This included 
54 phosphorylation sites that were significantly down-modulated after exposure to all three inhibitors, 
34 of which have not been previously reported. Functional analysis of these novel ERK targets identified 
roles for them in GTPase activity and regulation, apoptosis and cell-cell adhesion. Comparison of the 
results presented here with previously reported phosphorylation sites downstream of ERK showed 
a limited degree of overlap suggesting that ERK signaling responses may be highly cell line and cue 
specific. In addition we identified 26 phosphorylation sites that were only responsive to dabrafenib. We 
provide further orthogonal experimental evidence for 3 of these sites in human embryonic kidney cells 
over-expressing BRAF as well as further computational insights using KinomeXplorer. The validated 
phosphorylation sites were found to be involved in actin regulation, which has been proposed as a novel 
mechanism for inhibiting resistance development. These results would suggest that the linearity of the 
BRAF-MEK-ERK module is at least context dependent.
The ERK signaling network plays a central role in multiple cellular processes, including proliferation, differenti-
ation, development, learning survival and apoptosis1. Signalling is usually initiated by the small G protein RAS 
which transmits the signal to RAF kinases. In turn RAF kinases phosphorylate MAPK/ERK kinases (MEK) which 
phosphorylate ERK kinases2. In order for this relatively simple network to affect the many diverse, and conflict-
ing, cellular processes it controls, sophisticated regulatory mechanisms are required. Abnormalities in this regula-
tion have been shown to occur in many cancers. In fact RAF family kinases (ARAF, BRAF and RAF1) were among 
the first oncoproteins to be described approximately 30 years ago3. It is now known that BRAF mutations occur 
in a wide-range of cancers, particularly those with RAS mutations4. The highest frequency of BRAF mutations are 
found in malignant melanoma; approximately 50% of melanomas have BRAF mutations and approximately 90% 
of those are BRAFV600E 5. The BRAFV600E mutation results in the constitutive activity of BRAF deregulating the 
activation of its downstream effectors, including MEK and ERK, observations that have led to the development of 
small molecule inhibitors that target these kinases. These inhibitors are initially very effective at removing tumor 
burden, however they are rarely curative due to the rapid onset of drug resistance. Even though the mechanisms 
of resistance to therapy are diverse for each tumor, in more than two thirds of BRAFV600E positive tumors, MAPK 
signaling networks are reactivated6.
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Although phosphoproteomic studies identifying targets of ERK have recently been published the overlap 
between them has been relatively low7 and they have invariably focused on just one or two inhibitors. Given 
that it is well known that kinase signaling networks can be multivariate in nature8 we propose that in order 
to fully understand the complex responses of kinases to small molecule inhibition in an aberrant signalling 
context the systematic perturbation of the entire network is required. To that end, we here describe the global 
phospho-proteomic and proteomic analysis of A375 cells, harboring a mutated form of the BRAF kinase (V600E), 
treated with the BRAF inhibitor dabrafenib, the MEK inhibitor trametinib and the ERK inhibitor SCH772984 
(Fig. 1A). By inhibiting each member of the signaling network independently we provide unique insight into 
the flow of information through these proteins identifying novel effectors of BRAF and ERK. This proteomic 
analysis was combined with exome sequencing, an approach now commonly referred to as proteogenomics9. By 
constructing genome-specific spectra databases more proteins and phosphorylation sites can be identified due to 
the inclusion of mutated proteins and peptides, thus facilitating more accurate and comprehensive modeling of 
cancer signaling networks.
Results
Perturbation of the RAF-MEK-ERK signaling cascade. Distinct populations of cells were treated 
with either dabrafenib, trametinib or SCH772984 at EC100 concentration (500 nM for dabrafenib, 100 nM 
for trametinib and 500 nM for SCH772984) for 30 minutes (further details can be found in the Experimental 
Procedures). The time-point used was selected following western blot analysis of protein samples from A375 cells 
treated for 15 minutes, 30 minutes and 1 hour with dabrafenib, trametinib and SCH772984 (Figs 1B and S1). After 
treatment with dabrafenib we observed a significant decrease in phosphorylated MEK and ERK at all time points. 
After trametinib treatment we observed a significant decrease in phosphorylated MEK at 30 minutes and 1 hour, 
while there was a significant decrease in phosphorylated ERK at all time-points. After treatment with SCH772984 
we observed no significant change in the amount of phosphorylated MEK but did observe a significant decrease 
in ERK phosphorylation at all time points. We therefore selected the 30 minute time-point as the most optimal 
for further phosphoproteomic analyses as significant inhibition of phosphorylation was observed following treat-
ment with all three inhibitors.
Global phosphoproteomic analysis of the effects of RAF, MEK and ERK inhibitors on signaling. 
Modulation of cell signaling following inhibitor treatment was quantified using global phosphoproteomics and 
stable isotope labelling by amino acids in cell culture (SILAC) (Fig. 1C). In order to confirm that the A375 cells 
Figure 1. Method overview. (A) The BRAF, MEK, ERK kinase module was inhibited in 3 independent 
experiments using small molecule inhibitors specific to either BRAF (dabrafenib), MEK (trametinib) and 
ERK (SCH772984). (B) Analysis of the change in phosphorylation of MEK and ERK over time following 
drug treatment was assessed by western blot. Quantification of the density of the observed bands (shown in 
Supplementary Fig. S1) was performed in ImageJ. Data was normalized relative to the DMSO treated cells. (C) 
Cells were labelled with isotopomeric versions of the amino acids argenine and lysine. Following drug treatment 
cells were lysed and proteins extracted, digested and fractionated. Phosphorylated peptides were enriched using 
titanium dioxide prior to mass spectrometry analysis.
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were SILAC labelled, argenine and lysine incorporation, as well as proline conversion rates were monitored by 
determining the ratio of labelled peptides to unlabelled peptides in a test sample. We found that 98.6% of argi-
nine, and 98.7% of lysine, amino acids were SILAC labelled whilst proline conversion was 1.34% (Supplementary 
Fig. S2); given the extremely high level of SILAC incorporation it was determined that the potential for erroneous 
measurements due to inadequate labelling would be negligible10. SILAC ‘light’-labeled cells (Lys 0, Arg 0), treated 
with a vehicle control (dimethyl sulfoxide, (DMSO)), ‘medium’-labelled cells (Lys 4, Arg 6), a ‘super-SILAC’11 
mix of cells from all treatment conditions, along with the ‘heavy’-labeled (Lys8, Arg 10) drug treated cells were 
lysed in denaturing conditions (modified RIPA buffer with protease/phosphatase inhibitors) to prevent spurious 
kinase or phosphate activities. Cell lysates were quantified and mixed in a 1:1:1 ratio for each SILAC experiment 
and digested with Lys-C and trypsin. Peptides were then separated into fractions using strong cation exchange 
chromatography (SCX); seven SCX fractions were phospho-peptide enriched using titanium dioxide beads to 
enable the identification of occupied serine, threonine and tyrosine phosphorylation sites. Proteome analysis was 
performed using six SCX fractions in order to obtain global quantitative data on the relative protein abundances 
and to normalize phosphorylation levels to their respective protein levels. Samples were analysed by LC-MS/MS 
on a Q-Exactive Orbitrap mass spectrometer in biological triplicate; data was found to be consistent across the 
replicates with Pearson’s correlation coefficients ranging from 0.54 to 0.7 (Supplementary Fig. S2).
Identification of modulated phosphorylated peptides. Raw files were processed using MaxQuant 
1.5.0.212 selecting only the class I phosphorylation sites13 (Class I phosphorylation sites were defined by a local-
ization probability of 0.75 and a probability localization score difference greater than or equal to 5). Quantified 
ratios of median phophosite intensities were then calculated by dividing the intensity of the heavy samples by the 
intensity of the light samples. Similarly, phosphorylation site intensities were normalized to proteome by divid-
ing the phosphorylation site ratio by the ratio of heavy to light protein intensities. This normalization allowed 
the direct comparison of phosphorylated peptides following treatment by different inhibitors. These phospho/
proteome ratios were then log2 scaled such that negative ratios indicate a down-modulation of phosphorylation 
sites and positive ratios indicate an up-modulation. For example, a phosphorylation site with a log2(phosphoryl-
ation site H/L:protein H/L) ratio (log2FC) of −1 would have a 50% reduction in phosphorylation sites following 
inhibitor treatment compared to the DMSO control treatment, a fold-change of 0.5. Following this method we 
identified 7827 class I phosphorylation sites from at least one of the 9 conducted experiments (Supplementary 
Table S1). In order to further classify the modulated phosphorylation sites, as either up or down modulated, we 
ranked phosphorylation sites according to their log2FC ratio and the limma adjusted P value false-discovery 
rate (limma FDR). We established a ratio threshold by searching the observed phosphorylation sites for known 
effectors of ERK14–17, identifying phosphorylation sites on STMN1, TPR, RPS6KA1 and NUP153 all consist-
ently down-modulated after inhibitor treatment as well as phosphorylation sites on the ERK proteins themselves 
(Supplementary Table S2). From this analysis we determined that known effectors of ERK had at least a −0.7 
log2FC and a limma FDR less than 0.1 in our assay. We therefore used these thresholds to identify other signifi-
cantly modulated phosphorylation sites respective to inhibitor treatment (Fig. 2A–C). Globally, this analysis iden-
tified 301 down-modulated phosphorylation sites and 52 up-modulated phosphorylation sites (Fig. 2D). Only 
those phosphorylation sites that were significantly down-modulated in the presence of all three inhibitors were 
considered downstream effectors of ERK.
Identified effectors of ERK. We identified 54 phosphorylation sites down-modulated after treatment with 
dabrafenib, trametinib and SCH772984 (Fig. 2D and Supplementary Table S3). As these represent the most likely 
ERK effectors we compared this list to previously reported studies using human cancer cell lines7,18–21 and ERK1 
and ERK2 substrates reported in the PhosphoSitePlus database22 (Fig. 3). Of the 54 modulated phosphoryla-
tion sites identified, 34 have not been previously reported. We therefore sought to validate these 54 phospho-
rylation sites using computational and experimental means. We used KinomeXplorer23, a tool for predicting 
kinase-substrate relationships using sequence-based classifiers of linear motifs, to generate substrate predictions 
for ERK1 and ERK2. Of the 54 identified, 11 phosphorylation sites were found to have ERK1 or ERK2 as the high-
est KinomeXplorer prediction (Supplementary Table S4). In addition to this computational validation we also 
screened HEK293 cells over-expressing FLAG-tagged ERK1 or ERK2 in an affinity purification mass spectrome-
try experiment to identify protein-protein interactions24. Any proteins physically interacting with ERK1 or ERK2 
could then be identified by capturing the FLAG-tag using anti-FLAG beads. The success of the affinity purifica-
tion was validated by quantifying the intensity of ERK1 or ERK2; as expected we found a significant enrichment 
of ERK1 and ERK2 in their respective samples both with a z-score in excess of 5000. Of the 41 proteins (from the 
54 phosphorylation sites) identified in the A375 studies 13 could be validated as physically interacting with ERK1 
and/or ERK2 using affinity purification (Supplementary Table S5).
Analysis of changes occurring at the level of the proteome, following the same assessment criteria described 
above for the phosphorylation sites, found that no proteins were significantly regulated after treatment with all 
inhibitors (Supplementary Table S6).
Differentially modulated phosphorylation sites. While the combined analysis of the effect of the 
three inhibitors facilitated the reliable determination of downstream effectors of ERK we also investigated the 
signal propagation following inhibition with each of the three tested inhibitors individually. We identified 301 
phosphorylation sites that were differentially down-modulated by the three inhibitors, these were either known 
modulation sites upstream of ERK (such as the MEK sites, S218 and S222), known effectors of ERK that failed 
to pass the modulation threshold set, or BRAF/MEK/ERK-specific effectors (Fig. 4). The first two cases are illus-
trated in Fig. 4A; MEK S218 was downmodulated after BRAF and MEK inhibition but was not observed in all 
samples and thus did not pass the modulation threshold, MEK S222 was significantly down-modulated after 
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MEK inhibition, but as expected, was not significantly modulated after ERK inhibition. The known ERK feed-
back mechanism via the inhibitory site RAF1 S4325 also failed to pass the modulation threshold set for all 3 
independent experiments; this site was deemed significantly down-modulated after MEK and ERK inhibition 
(FDR < 0.1 and log2FC < −0.7), but was identified in only one of the biological replicates after BRAF inhibition 
(log2FC < −0.7) (Supplementary Table S1).
To determine the nature of the BRAF/MEK/ERK-specific effectors we selected the most significantly mod-
ulated phosphorylation sites (limma FDR < 0.05 and log2FC < −0.7) that were differentially modulated after 
treatment with dabrafenib, trametinib or SCH772984 alone (Supplementary Table S7). This identified 30 phos-
phorylation sites, the majority of which were modulated after treatment with dabrafenib (Fig. 4B). To further 
validate these phosphorylation sites we performed additional in silico and in vitro validation. As there was no 
public motif for BRAF one was generated using position-specific scoring matrices of FLAG-tagged BRAF isolated 
from mammalian cells (Supplementary Fig. S3). We found that BRAF did not have absolute specificity at any 
position but had a preference for Leucine and Methionine residues at the −3 position, hydrophobic residues at 
the +1 position and aromatic residues at the +2 position. Following the integration of this novel linear motif into 
NetPhorest/KinomeXplorer we found that, of the BRAF-specific effectors identified in this study, SPRY4 S125 was 
also predicted to be a BRAF substrate (Supplementary Table S8). In addition, the BRAF-specific effectors, CFL2 
S3, DSTN S3 and ZYX S259 were also found to have significantly modulated phosphorylation sites in a HEK293 
cell line over expressing BRAF (Supplementary Table S7).
Discussion
In this study we identified 54 effectors of ERK, just over half of which could be successfully validated either exper-
imentally, using physical interaction assays with ERK1/2, or computationally, from their linear motif. Despite 
this, we observed a relatively poor overlap with known ERK effectors, which is not unique to this investigation. 
By combining our data with previously reported studies7,18–21 we found a total of 1515 unique phosphorylation 
Figure 2. All identified phosphorylation sites observed following treatment with (A) dabrafenib, (B) trametinib 
or (C) SCH772984. Significantly modulated phosphorylation sites are shown in red, known effectors of 
ERK used to validate the dataset (as listed in Table S2) are shown in blue. (D) Number of down-modulated 
phosphorylation sites (limma FDR < 0.1 and log2FC < −0.7) and up-modulated phosphorylation sites (limma 
FDR < 0.1 and log2FC > 0.7) observed in each tested condition.
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sites (on 707 unique proteins) reported to be ERK effectors (Supplementary Table S9). It would seem likely that 
this is due to the complexity of the module and may suggest signaling responses which are multivariate in nature, 
dependent on the context of the model and cue given. In order to derive more functional insight from the novel 
phosphorylation sites observed in this study we imported the list of proteins into DAVID26,27. These previously 
unidentified phosphorylated proteins were found to have functional roles in GTPase activity and regulation, 
apoptosis and cell-cell adhesion, amongst others (Supplementary Table S10 and Supplementary Fig. S4). Given 
that these are known, albeit in some cases relatively understudied, areas of ERK signaling28–30 combined with the 
fact that there was a significant overlap of both computationally predicted substrates and direct interactors of 
Figure 3. Effect of known and novel ERK targets on the phosphorylation of BRAF, MEK and ERK. (A) Fold 
change in phosphorylation following inhibition with dabrafenib (a BRAF inhibitor) and trametinib (a MEK 
inhibitor). (B) Fold change in phosphorylation following inhibition with dabrafenib and SCH772984 (an 
ERK inhibitor). (C) Fold change in phosphorylation following inhibition with trametinib and SCH772984. 
In all cases ERK targets listed in PhosphositePlus are shown in blue, ERK targets reported by similar 
phosphoproteomic studies are shown in green. The 34 novel ERK targets passing fold change and false discovery 
rate thresholds in this assay are shown in red.
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ERK, identified in a drug independent manner, it would seem likely that the phosphorylation sites identified here 
are novel ERK effectors.
Whilst we identified significant numbers of novel phosphorylation sites we did not observe any significantly 
modulated proteins. This is perhaps unsurprising given the relatively short treatment time used in this assay. We 
did however find that APOB and THBS1 were significantly regulated after treatment with dabrafenib and that 
both proteins also decreased in concentration after treatment with trametinib and SCH772984, albeit not signifi-
cantly. APOB is a lipoprotein whose overproduction is a characteristic of insulin resistance, which can lead to type 
2 diabetes. This overproduction has previously been shown to be inhibited by ERK activation31. Similarly THBS1 
has been shown to be involved in epithelial-to-mesenchymal transition in melanoma and the development of 
drug resistance, both via the tumor cells themselves32 and also by protective mechanisms in melanoma-associated 
fibroblasts33. These data support the observations made in this study and indicate a potential role for these pro-
teins as diabetes and cancer therapeutic targets, respectively.
If the BRAF, MEK, ERK module is linear as suggested, then it should be expected that modulation of phospho-
rylation sites after treatment with BRAF and/or MEK inhibitors would also result in the modulation of these sites 
after ERK inhibition. Thus observations of differentially modulated phosphorylation sites must therefore either be 
erroneous, possibly caused by off-target effects of the inhibitors, or real, indicating that the network is not linear. 
‘Pathway analysis’ of the phosphorylated proteins identified following treatment with dabrafenib, trametinib or 
SCH772984 was performed using DAVID (Supplementary Fig. S4). We found significant overlap between the 
function of the three inhibitors centered around signal transduction, GTPase activity, tissue development, apop-
tosis and cell adhesion. Following BRAF inhibition by dabrafenib we also observed phosphorylation of proteins 
involved in cytoskeletal organization which is, at least in part, due to the validatable phosphorylation sites iden-
tified in our study as BRAF effectors (CFL2, DSTN and ZYX). STRING34 analysis of protein-protein interactions 
linking CFL2, DSTN and ZYK to BRAF showed that all three interact with actin (Fig. 4C) an interesting observa-
tion given that it has recently been shown that prolonged exposure to BRAF inhibitors results in changes in cell 
shape and that inhibiting these changes may overcome drug resistance35. Our results would thus suggest CFL2, 
DSTN and/or ZYK modulation as a mechanism for this regulation of actin. SPRY4, predicted to be a direct target 
of BRAF, is a member of the sprouty family of proteins that are well known as evolutionary conserved modulators 
of the MAPK/ERK module36. They are known to be deregulated in cancer and have been shown to play a role in 
the development, progression and metastasis of tumors, as well as the initial adaptive response to BRAF inhibi-
tors37. Recently it has been shown that SPRY4 is a transcriptional target of BRAFV600E 38, however the link between 
this transcriptional regulation and phosphorylation is currently unexplored. Given that the experimental valida-
tion for these phosphorylation sites was performed in the absence of drug, we can conclude that these were not 
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Figure 4. Phosphorylation patterns observed in this study. (A) Known phosphorylation sites observed in this 
study that did not pass the thresholds set. MEK S222 was significantly down-modulated after MEK inhibition, 
but as expected, was not significantly modulated after ERK inhibition. RAF1 S43, from the known inhibitory 
ERK feedback loop25, was found to be significantly modulated after trametinib and SCH772984 treatment but 
not dabrafenib. (B) We identified 26 phosphorylation sites that were significantly modulated following BRAF 
inhibition, but not after MEK and ERK and could thus be direct targets of BRAF. Of the 26 potential BRAF 
targets 3 could be validated by experimental means and 1 by computational means. The simplest STRING 
network illustrating their currently known interaction targets and BRAF is shown in (C).
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drug-specific observations. It should also be noted that the phosphorylation of DSTN by BRAF has been reported 
before7,17. Taken together, these data would suggest that BRAF kinase can recognize peptides, and thus potentially 
have a larger substrate space than previously thought. This would support the notion that the RAF-MEK-ERK 
module may, like many other signaling systems, rely on non-linear dynamic interactions depending on context.
Experimental Procedures
Cell culture. A375 (ATCC, CRL-1619) cells were SILAC labelled over 6 passages such that the incorpora-
tion level was above 95%. Cells were routinely passaged in T75 flasks and expanded into 15 cm dishes for mass 
spectrometry experiments. Cells were serum starved for 24 hours once they had grown to 80% confluency in the 
dishes. Serum was then added back to the cells for 24 hours prior to treatment with one of the three tested com-
pounds. Each treatment condition was repeated in triplicate with an associated DMSO control.
Drug treatments. Dabrafenib (Selleckchem, S2807), trametinib (Selleckchem, S2673) and SCH772984 
(Selleckchem, S7101) were diluted in DMSO to 500 μM, 100 μM and 500 μM concentrations respectively. 
Compounds were then aliquoted and stored at −80 °C. For cell treatment compounds were diluted 1/1000 in 
tissue culture medium and incubated with the cells for 30 minutes.
sample preparation. Sample preparation and TiO2 enrichment of phosphorylated peptides methods were 
based upon the protocol described in Schoof and Linding39. Cells were washed twice with 2 ml of ice-cold phos-
phate buffered saline before the addition of 1 ml of RIPA lysis buffer (50 mM Trizma hydrochloride (ph 7.5), 
150 mM NaCl, 1% v/v IGEPAL CA-630, 0.5% w/v sodium deoxycholate, 1 mM EDTA, 5 mM B-glycerophosphate, 
5 mM NaF, 1 mM Na3VO4, 1 Roche cOmplete, EDTA-free protease inhibitor cocktail per 10 ml). Cells were then 
sonicated in three 10 second bursts with an amplitude of 40% and then centrifuged at 4400 g for 20 minutes at 
4 °C. Cells and all buffers were maintained at 4 °C throughout the lysis procedure. Following centrifugation the 
supernatant was decanted into a clean tube and the pellet discarded, 40 ml of acetone was then added to the super-
natant and incubated at −20 °C overnight.
The following morning samples were centrifuged at 2000 g for 5 minutes at 4 °C, the supernatant was then 
discarded and the precipitate dissolved in 6 ml of urea buffer (6 M Urea, 2 M Thiourea, 10 mM HEPES pH 8). 
The sample was incubated at room temperature on a rotating platform until all protein had dissolved, if the 
precipitate did not dissolve supernatant was aspirated and additional urea buffer was added to facilitate this step. 
Protein concentration was then determined using the Qubit Protein Assay Kit (ThermoFisher Scientific), accord-
ing to the manufacturers instructions. Samples were then mixed such that the resulting solution contained equal 
amounts (8 mg) of each of the ‘heavy’, ‘medium’ and ‘light’ SILAC labeled samples. 1 mM Dithiothritol was then 
added to this mixture and incubated for 1 hour on a rotating platform at room temperature. Chloroacetamide was 
then added at 1 in 100 dilution and incubated for 1 hour on a rotating platform at room temperature. Following 
this Lys-C protease (Wako Chemical Corporation, 129-02541) was added to the sample at a ratio of 1:200 (pro-
tease:substrate) and incubated for 4 hours on a rotating platform at room temperature. Samples were then diluted 
4-fold in 50 mM ammonium bicarbonate (pH 8) prior to the addition of trypsin (Sigma-Aldrich, T6567) at a ratio 
of 1:200 (protease:substrate). Samples were then incubated overnight on a rotating platform at room temperature.
The following morning trifluoroacetic acid was added to the sample to give a 2% final concentration, the 
pH of the sample was then checked to confirm that it was below 2.5, with additional trifluoroacetic acid added 
as required. The sample was then centrifuged at 2000 g for 5 minutes and the supernatant decanted into a clean 
tube before being added to a 55–105 μm Sep-Pak C18 cartridge (Waters, WAT020515) that had been prewashed 
with 5 ml of acetonitrile and two 4 ml washes of 0.1% trifluoroacetic acid. After sample loading the cartridge was 
washed three times with 6 ml of 0.1% trifluoroacetic acid. Sample was then eluted in two 2 ml volumes of 60% 
acetonitrile, 0.1% trifluoroacetic acid and 2 ml of 80% acetonitrile, 0.1% trifluoroacetic acid. In all cases pressure 
was applied to the Sep-Pak such that flow rate was even and no greater than 0.5 ml per minute.
tio2 enrichment of phosphorylated peptides. Samples eluted from the Sep-Pak were then fractionated 
using strong cation exchange chromatography generating 32 fractions. Fractions 1 to 6, 7 to 11, 17 to 19, 20 to 25, 
26 to 27 and 28 to 32 were pooled and, along with the individual fractions 12 to 16, 1.5 mg of titanium dioxide 
beads (GL Sciences, 5020–75000) in 6 μl DHB buffer (20 mg/ml 2,5-dihydroxybenzoic acid, 5% trifluoroacetic 
acid, 30% acetonitrile) were added. Samples were mixed with the titanium beads for 30 minutes on a rotating plat-
form before being centrifuged at 2000 g for 5 minutes. The supernatant from fractions 1 to 6 and 7 to 11, fractions 
12 to 14 and fractions 15 to 16 were decanted into a new tube and an additional 1.5 mg of titanium dioxide beads 
added and mixed for 30 minutes on a rotating platform. The supernatant from fractions 1 to 6 and 7 to 11 were 
decanted into a new tube with an additional 1.5 mg of titanium dioxide beads and mixed again for 30 minutes 
on a rotating platform. In total this generated 15 titanium bead samples. Following mixing supernatant was dis-
carded and the titanium beads resuspended in 100 μl of 5 mM potassium dihydrogen phosphate, 30% acetonitrile, 
350 mM KCl, pH 2.7 (with trifluoroacetic acid).
Samples were then centrifuged at 2000 g for 5 minutes, the supernatant aspirated and the beads resuspended 
in 100 μl of 40% acetonitrile, 0.25% acetic acid, 0.5% trifluoroacetic acid. Samples were again centrifuged at 2000 
g for 5 minutes, supernatant discarded and the beads resuspended in 50 μl of 80% acetonitrile, 0.5% acetic acid. 
Suspended beads were transferred to a C8 stage tip and centrifuged at 1000 g for 30 seconds and repeated until 
all liquid had passed through the stage tip. Samples were then eluted from the beads into a pcr microplate using 
20 μl of 5% ammonia and 20 μl of 10% ammonia, 25% acetonitrile with the eluent from stage tips 3 and 4, 5 and 
6, 7 and 8 and 10 and 11 mixed to give a total of 11 samples. Volumes were normalised by the addition of 40 μl of 
acidification buffer (1% trifluoroacetic acid, 5% acetonitrile) to wells containing eluent from only one stage tip. 
Plates were then spun in a centrifugal evaporator until 5–10 μl of buffer remained, approximately 65 minutes.
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For proteome analysis six samples were collected; 10 μl of sample prior to strong cation exchange fractiona-
tion, 10 μl from the fraction 1–6 pool, 10 μl from the fraction 7–11 pool, 10 μl from fractions 12 to 15 (2.5 μl from 
each), 10 μl from fraction 16 and the fraction 17–19 pool (5 μl from each) and 10 μl from the fraction 20–25, 
26–27 and 28–32 pools (3.5 μl from each).
C18 stage tips were prepared by the addition of 20 μl of methanol centrifuged through the tip at 1000 g for 
30 seconds. Stage tips were then washed with 20 μl 80% acetonitrile, 0.1% formic acid, 1000 g for 30 seconds and 
20 μl of 3% acetonitrile, 1% trifluoroacetic acid, twice, again at 1000 g for 30 seconds. Samples were resuspended in 
acidification buffer, 20 μl for those containing a single eluent and 40 μl for pooled eluents. Plates were centrifuged 
for 1 minute to condense the sample, which was then transferred to the stage tip. Stage tips were centrifuged for 
30 seconds at 1000 g and repeated until all sample had passed through the stage tip. Samples were the washed by 
the addition of 20 μl of 0.1% formic acid to the stage tips, before centrifugation at 1000 g for 30 seconds. This wash 
was then repeated a second time. Samples were then eluted from the stage tips into a pcr microplate using 20 μl 
of 80% acetonitrile, 0.1% formic acid, twice, for pooled samples and 40 μl of 80% acetonitrile, 0.1% formic acid, 
twice, for single samples. Eluent from stage tips 2 and 8, 3 and 4, 6 and 7 and 9 and 10 were mixed to give a total 
of 7 samples. Plates were then spun in a centrifugal evaporator for 35 minutes before the addition of 4 μl of 40% 
acetonitrile, 0.25% acetic acid, 0.5% trifluoroacetic acid. Plates were then centrifuged for 1 minute to condense the 
sample and analysed on a ThermoFisher Scientific Q Exactive mass spectrometer.
Affinity purification. HEK293 cells were transfected with FLAG-tagged ERK1, ERK2 and control (red flu-
orescent protein) protein using the Flp-In T-Rex system (ThermoFisher Scientific. Gene expression was induced 
with tetracyclin for 72 hours prior to affinity purification sample preparation according to the protocol described 
in Lambert et al.40 with some minor alterations. Cells were washed with 4 ml of PBS before being scraped off the 
dish into 1 ml PBS using a rubber spatula. Cells from two 150 mm plates were pelleted by centrifugation, the 
supernatant removed and the pellet weighed before being frozen on dry ice and kept at −80 °C until ready to 
be used (pellet weights for samples used in this assay were 287, 302 and 338 mg for ERK1 triplicate repeats, 288, 
284 and 377 mg for ERK2 and 282, 292 and 364 mg for control samples). Cells were lysed by resuspension in 1:4 
(pellet weight/volume) ratio of lysis buffer (50 mM HEPES-NaOH (pH 8.0), 100 mM KCl, 2 mM EDTA, 0.2% 
NP40, 10% glycerol, 5 mM β-glycerophosphate, 5 mM sodium fluoride, 1 mM sodium orthovanadate and pro-
tease inhibitor cocktail (Sigma-Aldrich, 000000004693159001, 1 tablet/10 ml) followed by two freeze/thaw cycles 
and sonication at 20% amplitude for two 10 second bursts with a 3 mm probe. Samples were split into two and half 
was treated with 1 μl benzonase (250 units/μl) for 1 hour (4 °C on a rotator). Fractions were then recombined and 
the resulting cell extract was then clarified by centrifugation at 4500 RCF for 20 min (4 °C) before transferring 
the supernatant to a fresh tube. Affinity purifications were performed by incubating the cleared lysate with 25 μl 
of pre-washed magnetic M2 anti-FLAG beads (Sigma-Aldrich) for 2 hours at 4 °C on a rotator. Beads were then 
washed four times with 1 ml of 20 mM Tris-HCl pH 8 2 mM CaCl2 before being centrifuged (500 g for 1 minute) 
and any residual liquid removed.
For mass spectrometry analysis, samples underwent on-bead digestion. Beads were first resuspended in 
20 μl of Tris-HCl buffer (pH 8) prior to the addition of 1 μg of Lys-C protease (Wako Chemical Corporation, 
129–02541). Cells were incubated with the Lys-C for 3 hours on a rotator. Following this, 1 μg of trypsin 
(Sigma-Aldrich, T6567) was added to the sample and incubated for approximately 16 hours on a rotator at room 
temperature. The following morning, 1.2 μl of 50% formic acid was added to the samples to stop digestion and 
20 μl of acidification buffer added to each sample. C18 stage tips were prepared by the addition of 20 μl of meth-
anol centrifuged through the tip at 400 g for 35 seconds. Stage tips were then washed with 20 μl 80% acetonitrile, 
0.1% formic acid, 400 g for 35 seconds, and 250 μl of 3% acetonitrile, 1% trifluoroacetic acid at 600 g for 1 minute. 
Samples were resuspended in 20 μl of acidification buffer and transferred to the stage tip. Stage tips were centri-
fuged for 1 minute at 600 g. Samples were then washed by the addition of 100 μl of 0.1% formic acid to the stage 
tips, centrifuged through at 800 g for 1 minute. This wash was then repeated a second time. Samples were then 
eluted from the stage tips into a pcr microplate using 40 μl of buffer B. Plates were then spun in a centrifugal evap-
orator for 65 minutes and analysed on a ThermoFisher Scientific Q Exactive mass spectrometer.
Mass spectrometry. Approximately 1 μg of peptides from each proteome or phospho-proteome sample 
was loaded onto a 50 cm C18 EasySpray column (ThermoFisher Scientific, ES803) using an Easy-nLC 1000 
(ThermoFisher Scientific) with the column oven set at 45°C and a flow rate of 250 nl/min. Phospho-proteome 
samples were eluted over a 250 minute gradient ranging from 5% to 50% acetonitrile. The Q Exactive was run 
in DDA-MS2 top10 method with full MS spectra collected at a resolution of 70,000, a scan range of 300 to 1750 
m/z and an AGC target of 3 × 106 or 20 ms maximum injection time. MS2 spectra were obtained at a resolution 
of 17,500 and an AGC target of 1 × 106 or 80 ms maximum injection time. Dynamic exclusion was set to 20 sec-
onds and ions with a charge state less than 2, or unknown, were excluded. For proteome analyses gradient time 
was decreased to 240 minutes, maximum MS injection time was decreased to 60 ms and dynamic exclusion was 
increased to 45 seconds, all other settings were identical.
Mass spectrometry searches. Raw files were processed using MaxQuant 1.5.0.2 with all searches con-
ducted using an A375-specific database, where all protein sequence variants were included in addition to the 
reference, Ensemble version 68 human FASTA, sequences (see FASTA file generation for details). Methionine oxi-
dation, protein N-terminal acetylation and serine/threonine/tyrosine phosphorylation were set as variable mod-
ifications and cysteine carbamidomethylation was set as a fixed modification. False discovery rates were set to 1% 
and the ‘match between runs’ functionality was activated. The medium labeled super SILAC control was included 
in order to maximize SILAC ratio coverage, it was included in all searches but was not utilized for further analysis.
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FASTA file generation. A375 cells were grown to 80% confluence in T75 flasks. DNA was extracted from 
the cells using a Qiagen QIAamp DNA mini kit according to the manufacturers instructions. Sample was then 
sent to Beckman Coulter Genomics (now GENEWIZ) for sequencing. Target enrichment was performed using 
SureSelect whole exome version 5 and sequencing was performed using an Illumina system at 2 × 100 base pair 
reads, 89x average coverage with a minimum of 10x coverage at 95% of the sample.
Reads were filtered with Trimmomatic41 using the following parameters: headcrop = 3, minlen = 30, trail-
ing = 3. Trimmed reads were aligned to the hg19 reference genome using the Burows-Wheeler Alignment tool42 
before the application of the Genome Analysis Toolkit43 base quality score recalibration, indel realignment, dupli-
cate removal, and SNP and INDEL discovery and genotyping across all samples simultaneously using standard 
hard filtering parameters according to Genome Analysis Toolkit best practices recommendations44. The Ensembl 
Variant Predictor45 was used to predict the effect of the mutations on the protein sequence and those passing a 
high sensitivity filter (QD ≤ 1.5, FS ≥ 60, MQ ≥ 40, MQRankSum ≤ −12.5, ReadPosRankSum ≤ −8 and DP ≥ 5 
per sample on average) were added to the search FASTA file.
Statistical analysis. Phosphorylation sites were assessed for significance using the limma FDR, a moderated 
t-test implemented in the limma package for Bioconductor (http://www.bioconductor.org). Significance p-values 
obtained were corrected for multiple testing by the false-discovery method46 and deemed significant at an FDR 
threshold of 0.1. Functional enrichment analysis was performed using DAVID with a background list comprised 
of the 4960 proteins identified in the mass spectrometry experiments. The resulting Gene Ontology terms were 
visualized using REVIGO47.
Western blotting. 4–12% Bis-Tris gels were transferred to PVDF transfer membranes and blocked for 
1 hour with PBS-Tween containing 5% (w/v) milk powder. Primary antibodies were mouse anti-MEK (4694, Cell 
Signaling), mouse anti-ERK (9107, Cell Signaling), rabbit anti-RSK1/RSK2/RSK3 (9355, Cell Signaling), rab-
bit anti-phospho-MEK1/2 (Ser217/221, 9154, Cell Signaling) and rabbit anti-phospho-p44/42 MAPK (Thr202/
Tyr204, 9101, Cell Signaling). Primary antibodies were added to membranes and incubated overnight at 4 °C 
at 1:1000, except for the anti-ERK antibody, which was used at 1:2000. Secondary antibodies were horserad-
ish peroxidase-conjugated sheep anti-mouse (ab6808, Abcam) and horseradish peroxidase-conjugated goat 
anti-rabbit (ab6721, Abcam) immunoglobulin G (both used at 1:2000). Quantification was performed using 
ImageJ with the Analyze/Gels tool used to firstly define each lane. Plot Lanes was then used to create density plots 
of each designated lane. The Line and Hand tools were then used to remove background noise and calculate the 
area under the peak respectively. All data points were then expressed relative to the DMSO control.
Peptide array analysis of BRAF phosphorylation site specificity. BRAF specificity was analyzed 
using an arrayed positional scanning peptide library as previously described48. Briefly, the library consisted of 180 
peptide mixtures having the general sequence Y-A-x-x-x-x-x-S/T-x-x-x-x-A-G-K-K(biotin), where “x” indicates 
an equimolar mixture of the 17 amino acids excluding Cys, Ser and Thr. Each mixture had one “x” position fixed 
as one of the 20 amino acids. Peptide mixtures (50 µM) were incubated for 2 h at 30 °C with FLAG-BRAF-V600E 
(affinity purified from transiently transfected HEK293T cells as described) in a reaction buffer containing 50 mM 
HEPES, pH 7.4, 5 mM MgCl2, 5 mM MnCl2, 1 mM DTT, 0.1% Tween 20, and 50 µM [γ-33P]ATP (50 µCi/ml). 
Aliquots (200 nl) of each reaction were then transferred to a streptavidin-coated membrane (Promega), which 
was washed, dried, and exposed to a phosphor storage screen as described. Radiolabel incorporation into each 
peptide was quantified using QuantityOne software (BioRad). Quantified data were normalized to an average 
value of unity within each peptide position and log2 transformed. The heat map (generated in Microsoft Excel) 
shows data averaged from 2 independent assays.
Data Availability
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE 
partner repository with the dataset identifier PXD013923. The exome sequencing data have been deposited to the 
Sequence Read Archive with the accession PRJNA544116. All other data needed to evaluate the conclusions in 
the paper are present in the paper or the supplementary materials.
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